Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Literature DB >> 213392

Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

H Heremans, A Billiau, A Colombatti, J Hilgers, P de Somer.

Abstract

The effect of long-term administration of interferon in New Zealand Black and New Zealand Black/New Zealand White F1 hybrid mice was studied. Treatment with moderate doses of interferon (10(4) units, five times weekly for 8 weeks) did not depress murine leukemia virus gp69/71 levels in serum and spleen, nor p30 levels in the spleen. Interferon given at 10(5.1) units (three times weekly for 37 weeks) caused an increased incidence of anti-erythrocyte antibodies in New Zealand Black mice. Finally, the hybrid mice given interferon at 10(6.0) units (three times weekly for 33 weeks) had increased renal immune complex deposits and increased incidences of proteinuria and anemia.

Entities: Disease Species

Mesh：

Substances：

Year: 1978 PMID： 213392 PMCID： PMC422085 DOI： 10.1128/iai.21.3.925-930.1978

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

20 in total

1. Oncornavirus envelope glycoprotein in serum of mice.

Authors: M Strand; J T August
Journal: Virology Date: 1976-11 Impact factor: 3.616

2. Progressive glomerulonephritis in mice treated with interferon preparations at birth.

Authors: I Gresser; C Maury; M Tovey; L Morel-Maroger; F Pontillon
Journal: Nature Date: 1976-09-30 Impact factor: 49.962

3. Accelerated mortality in young NZB/NZW mice treated with the interferon inducer tilorone hydrochloride.

Authors: S E Walker
Journal: Clin Immunol Immunopathol Date: 1977-09

4. Influence of interferon on virus particle formation in different oncornavirus carrier cell lines.

Authors: A Billiau; H Sobis; P De Somer
Journal: Int J Cancer Date: 1973-11-15 Impact factor: 7.396

5. Interferon-induced skin reactivity in man.

Authors: P De Somer; V G Edy; A Billiau
Journal: Lancet Date: 1977-07-02 Impact factor: 79.321

6. Synthesis and cleavage processing of oncornavirus proteins during interferon inhibition of virus particle release.

Authors: S Z Shapiro; M Strand; A Billiau
Journal: Infect Immun Date: 1977-06 Impact factor: 3.441

7. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors: L A Aarden; E R de Groot; T E Feltkamp
Journal: Ann N Y Acad Sci Date: 1975-06-30 Impact factor: 5.691

8. Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice.

Authors: Y Rivière; I Gresser; J C Guillon; M G Tovey
Journal: Proc Natl Acad Sci U S A Date: 1977-05 Impact factor: 11.205

9. Pathogenesis of the glomerulonephritis of NZB/W mice.

Authors: P H Lambert; F J Dixon
Journal: J Exp Med Date: 1968-03-01 Impact factor: 14.307

10. Further implication of murine leukemia-like virs in the disorders of NZB mice.

Authors: R C Mellors; T Aoki; R J Huebner
Journal: J Exp Med Date: 1969-05-01 Impact factor: 14.307

30 in total

1. Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.

Authors: Ming You; Guanjun Dong; Fanlin Li; Feiya Ma; Jing Ren; Yujun Xu; Huimin Yue; Ruijing Tang; Deshan Ren; Yayi Hou
Journal: Cell Mol Immunol Date: 2015-08-17 Impact factor: 11.530

2. Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery.

Authors: Jessica K Gordon; Cynthia Magro; Theresa Lu; Robert Schneider; April Chiu; Richard R Furman; Garron Solomon; Anne Bass; Doruk Erkan
Journal: HSS J Date: 2009-07-16

Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

1. Oncornavirus envelope glycoprotein in serum of mice.

2. Progressive glomerulonephritis in mice treated with interferon preparations at birth.

3. Accelerated mortality in young NZB/NZW mice treated with the interferon inducer tilorone hydrochloride.

4. Influence of interferon on virus particle formation in different oncornavirus carrier cell lines.

5. Interferon-induced skin reactivity in man.

6. Synthesis and cleavage processing of oncornavirus proteins during interferon inhibition of virus particle release.

7. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

8. Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice.

9. Pathogenesis of the glomerulonephritis of NZB/W mice.

10. Further implication of murine leukemia-like virs in the disorders of NZB mice.

1. Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.

2. Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery.

Review 3. Role of type I interferons in the activation of autoreactive B cells.

Review 4. The interferon system as a basis for antiviral therapy or prophylaxis.

5. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus.

Review 6. New roles for the major human 3'-5' exonuclease TREX1 in human disease.

7. Isoprinosine delays the early appearance of autoimmunity in NZB/NZW F1 mice treated with interferon.

8. Induction of interferon by levamisole and concanavalin A in HA/ICR and NZB/W mouse spleen cells.

9. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis.

10. Renal deposition of alpha interferon in systemic lupus erythematosus.